Biosimilars 102 - Litigation: Planning and Strategy

This year, the FDA approved the first biosimilar drug under the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and the courts have recently rendered some important statutory interpretations. This represents the dawn of a new era in the approval and marketing of biologic products. Join Fish attorneys for a multi-part webinar series designed to help you navigate these yet unsettled waters of dealing with biologic products.

The second webinar in the series will build on the first webinar and cover recent court cases related to biologics. Join Fish principals Terry Mahn and Chad Shear as they discuss:

• Preparing for litigation
• The “Patent Dance”
• Strategies that pioneers and biosimilar companies should be implementing now

This series will prove valuable for those already familiar with the BPCIA as well as for those just starting to grapple with its provisions.